GARP Research Reaffirms Buy Rating on Edwards Lifesciences (EW)

By admin | 6 years ago

Edwards Lifesciences (NYSE: EW)‘s stock had its “buy” rating restated by analysts at GARP Research in a research report issued to clients and investors on Monday.

A number of other firms have also recently commented on EW. Analysts at Zacks reiterated a “neutral” rating on shares of Edwards Lifesciences in a research note to investors on Friday. They now have a $86.00 price target on the stock. Separately, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Edwards Lifesciences in a research note to investors on Wednesday, March 21st. Finally, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Edwards Lifesciences in a research note to investors on Thursday, March 8th.

The company last announced its quarterly results on Thursday, February 2nd. It reported $0.62 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.59 EPS by $0.03. The company’s quarterly revenue was up 9.6% on a year-over-year basis.

Edwards Lifesciences Corporation (Edwards Lifesciences) is a global player in products and technologies designed to treat advanced cardiovascular disease.

About the author